Global Intra-Uterine Contraceptive Devices Market is expected to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024.
- Advertising -
“Global Intra-Uterine Contraceptive Devices Market” is expected to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
The global injectable drug deli IUCD very market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Bayer AG dominated the IUCD devices market accounting for a highest market share in 2016, followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V.
- Advertising -
BAYER HEALTHCARE AG
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science.
The HealthCare segment offers a wide range of products under animal health, pharmaceuticals, consumer care, and medical care. The pharmaceutical business offers a wide range of products in the therapeutic area of oncology, haematology, and ophthalmology, and offers products for women’s health and cardiology therapeutic applications
- In October 2016, Bayer AG has successfully concluded the European registration procedure to gain EUwide marketing authorization for its new low-dose levonorgestrel-releasing intrauterine system (LNGIUS). The product is named Kyleena and will be available in the market from 2017 January.
- In September 2016, Bayer AG has successfully received FDA approval for its new low-dose levonorgestrel releasing intrauterine system (LNG-IUS) “Kyleena” The launch of this product in October in U.S.
Inquiry for TOC Visit @ databridgemarketresearch.com/toc/?dbmr=global-intra-uterine-contraceptive-devices-market
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Established in 1901 and headquartered in Petah Tikva, Israel, Teva is one of the leading global companies in IUCD devices market. The company is engaged in developing, producing, and marketing affordable generic drugs as well as innovative and specialty pharmaceutical ingredients.
Teva operates through two business segments, namely generic medicine and specialty medicine. Teva's specialty medicines business focuses on central nervous system (CNS), respiratory oncology, pain, and women's health therapeutic areas as well as biologics.
MONA LISA N.V.:
Mona Lisa N.V. was founded in 1996, and is a subsidiary for Eurim Pharma headquarterd in Germany. Prior to 1996 the company was known as Homesteel-Achel which was an exclusive sub-manufacturer for Organon from 1980 to 1996.
Mona Lisa specializes in manufacturing class II and III medical devices used in the field of gynecology. Mona Lisa N.V products are Copper-Intrauterine-Devices (IUD), Aspiration needles and Consultation services / sub-manufacturing services.
Browse Full Report Visit @ databridgemarketresearch.com/reports/global-intra-uterine-contraceptive-devices-market/
Category: Market Research Publishers and RetailersCompany profile: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...
For more information: